Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2022, with the report dated October 14, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| 2022-10-12 | American Depositary Shares (ADSs) | $30.5900 | 2,217.145 | New York Stock Exchange (XNYS) |
Note: The total volume represents the aggregate of three separate transactions executed at the same price on the same date.
Material Changes
The filing does not report material changes to the company's financial position or operations. It details routine acquisitions of ADSs by three executives following the re-investment of dividends paid to shareholders on October 6, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a statutory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from dividend re-investment plans, not open-market purchases.
- Executives Involved:
- Dr. H. Barron (Non-Executive Director): Acquired 1,803.714 ADSs.
- Mr. J. Ford (SVP and Group General Counsel): Acquired 350.735 ADSs.
- Shobie Ramakrishnan (Chief Digital and Technology Officer): Acquired 62.696 ADSs.
- Market Price: The transactions occurred at a uniform price of $30.59 per ADS on October 12, 2022.
- Financial Data: This filing does not provide any quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial results.